JPWO2020047352A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020047352A5
JPWO2020047352A5 JP2021510984A JP2021510984A JPWO2020047352A5 JP WO2020047352 A5 JPWO2020047352 A5 JP WO2020047352A5 JP 2021510984 A JP2021510984 A JP 2021510984A JP 2021510984 A JP2021510984 A JP 2021510984A JP WO2020047352 A5 JPWO2020047352 A5 JP WO2020047352A5
Authority
JP
Japan
Prior art keywords
hae
composition
antibody
treatment period
prior
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021510984A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021535161A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/048961 external-priority patent/WO2020047352A1/fr
Publication of JP2021535161A publication Critical patent/JP2021535161A/ja
Publication of JPWO2020047352A5 publication Critical patent/JPWO2020047352A5/ja
Priority to JP2024094996A priority Critical patent/JP2024113183A/ja
Pending legal-status Critical Current

Links

JP2021510984A 2018-08-30 2019-08-30 血漿カリクレイン阻害剤及び遺伝性血管浮腫発作を処置するためのその使用 Pending JP2021535161A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024094996A JP2024113183A (ja) 2018-08-30 2024-06-12 血漿カリクレイン阻害剤及び遺伝性血管浮腫発作を処置するためのその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862725216P 2018-08-30 2018-08-30
US62/725,216 2018-08-30
US201962808612P 2019-02-21 2019-02-21
US62/808,612 2019-02-21
PCT/US2019/048961 WO2020047352A1 (fr) 2018-08-30 2019-08-30 Inhibiteurs de la kallicréine plasmatique et leurs utilisations pour traiter une crise d'angio-œdème héréditaire

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024094996A Division JP2024113183A (ja) 2018-08-30 2024-06-12 血漿カリクレイン阻害剤及び遺伝性血管浮腫発作を処置するためのその使用

Publications (2)

Publication Number Publication Date
JP2021535161A JP2021535161A (ja) 2021-12-16
JPWO2020047352A5 true JPWO2020047352A5 (fr) 2022-09-05

Family

ID=67953889

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021510984A Pending JP2021535161A (ja) 2018-08-30 2019-08-30 血漿カリクレイン阻害剤及び遺伝性血管浮腫発作を処置するためのその使用
JP2024094996A Pending JP2024113183A (ja) 2018-08-30 2024-06-12 血漿カリクレイン阻害剤及び遺伝性血管浮腫発作を処置するためのその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024094996A Pending JP2024113183A (ja) 2018-08-30 2024-06-12 血漿カリクレイン阻害剤及び遺伝性血管浮腫発作を処置するためのその使用

Country Status (12)

Country Link
US (2) US20200109214A1 (fr)
EP (1) EP3843840A1 (fr)
JP (2) JP2021535161A (fr)
KR (1) KR20210053928A (fr)
CN (1) CN113056304A (fr)
AU (1) AU2019328324A1 (fr)
BR (1) BR112021003789A2 (fr)
CA (1) CA3110689A1 (fr)
IL (1) IL281063A (fr)
MA (1) MA53490A (fr)
MX (1) MX2021002349A (fr)
WO (1) WO2020047352A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102320178B1 (ko) 2011-01-06 2021-11-02 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 결합 단백질
CA2906624A1 (fr) 2013-03-15 2014-09-25 Dyax Corp. Anticorps anti-kallicreine plasmatique
WO2015148790A1 (fr) 2014-03-27 2015-10-01 Dyax Corp. Compositions et procédés pour le traitement de l'oedème maculaire diabétique
NZ744233A (en) 2015-12-11 2023-11-24 Takeda Pharmaceuticals Co Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
JP2023510854A (ja) * 2020-01-13 2023-03-15 武田薬品工業株式会社 小児遺伝性血管性浮腫発作を治療するための血漿カリクレイン阻害剤及びその使用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
AU675916B2 (en) 1991-06-14 1997-02-27 Genentech Inc. Method for making humanized antibodies
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
JP3805785B2 (ja) 1994-01-11 2006-08-09 ダイアックス コープ. カリクレイン阻害クニッツドメイン蛋白質およびその相同体
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
WO2003103475A2 (fr) 2002-06-07 2003-12-18 Dyax Corp. Prevention et reduction de la perte sanguine
KR102320178B1 (ko) * 2011-01-06 2021-11-02 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 결합 단백질
CA2906624A1 (fr) * 2013-03-15 2014-09-25 Dyax Corp. Anticorps anti-kallicreine plasmatique
WO2015148790A1 (fr) * 2014-03-27 2015-10-01 Dyax Corp. Compositions et procédés pour le traitement de l'oedème maculaire diabétique
EP3286226A4 (fr) * 2015-03-30 2018-12-05 Dyax Corp. Inhibiteurs de la kallicréine plasmatique et utilisations desdits inhibiteurs pour prévenir un accès d'angio-oedème héréditaire
NZ744233A (en) * 2015-12-11 2023-11-24 Takeda Pharmaceuticals Co Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
WO2017106679A1 (fr) * 2015-12-18 2017-06-22 Graco Minnesota Inc. Installation de soufflet et procédé de maintien

Similar Documents

Publication Publication Date Title
JP2022033868A5 (fr)
JP2019501886A5 (fr)
US20240052058A1 (en) Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x
Gurfinkel et al. Flu vaccination in acute coronary syndromes and planned percutaneous coronary interventions (FLUVACS) Study
JP2020002171A5 (fr)
Weitz Factor XI and factor XII as targets for new anticoagulants
JP2018514510A5 (fr)
JPWO2020047352A5 (fr)
JPWO2020186132A5 (fr)
UA127588C2 (uk) Способи застосування та композиції, які містять дулаглутид
KR20170118830A (ko) 조현병의 치료를 위한 일로페리돈
IL296872A (en) Preventive treatment for migraine
AU2016221627A1 (en) Pharmaceutical formulations of C1 esterase inhibitor
JPWO2021146160A5 (fr)
RU2021129732A (ru) Ингибиторы плазменного калликреина и их применение для лечения приступа наследственного ангионевротического отека
US20210338766A1 (en) Methods of treating multiple myeloma
JPWO2019215701A5 (fr)
WO2021255438A1 (fr) Combinaison de dexaméthasone et d'un antagoniste du récepteur des minéralocorticoïdes destinée à être utilisée dans le traitement du syndrome de détresse respiratoire aiguë
EP4069737A2 (fr) Procédés de traitement de lichen plan à l'aide d'antagonistes de l'interleukine 17 (il-17)
CN118556078A (zh) 通过使用抗c5抗体可伐利单抗用于治疗或预防格林-巴利综合征的剂量及施用方案
WO2021108862A1 (fr) Utilisation d'un anticorps anti-facteur xii pour le traitement ou la prévention de l'oedème de quincke héréditaire
RU2022101306A (ru) Схема введения доз и виды комбинированной терапии для полиспецифических антител, нацеленных на антиген созревания в-клеток
Reisch et al. Use of Angiotensin-Converting Enzyme Inhibitors for the Preservation of Kidney Function
MX2011000673A (es) Uso de idrabiotaparinux para disminuir la incidencia de hemorragias durante un tratamiento antitrombotico.
JPWO2021067297A5 (fr)